Antony Pfaffle

Antony Pfaffle

Auto-generated profile, based on publicly available information

Antony Pfaffle

CorMedix Inc., Berkeley Heights, New Jersey, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2023 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Open access
AAAnil K. Agarwal
Anil K. Agarwal
PRPrabir Roy-Chaudhury
Prabir Roy-Chaudhury
PMPhoebe Mounts
Phoebe Mounts
EHElizabeth Hurlburt
Elizabeth Hurlburt
APAntony Pfaffle
Antony Pfaffle
EPEugene C. Poggio
Eugene C. Poggio
Background: Catheter‐related bloodstream infections (CRBSIs) are one of the most prevalent, fatal, and costly complications of hemodialysis with a central venous catheter (CVC). The LOCK IT-100 trial compared the efficacy and safety of a taurolidine/heparin catheter lock solution that combines taurolidine 13.5 mg/ml and heparin (1000 units/ml) versus heparin in preventing CRBSIs in participants receiving hemodialysis via CVC. Methods: LOCK IT-100 was a randomized, double-blind, active-control, multicenter, phase 3 study that enrolled adults with kidney failure undergoing maintenance hemodialysis via CVC from 70 US sites. Participants were randomized 1:1 to taurolidine/heparin catheter lock solution or heparin control catheter lock solution (1000 units/ml). The primary end point was time to CRBSI as assessed by a blinded Clinical Adjudication Committee. Secondary end points were catheter removal for any reason and loss of catheter patency. On the basis of a prespecified interim analysis, the Data and Safety Monitoring Board recommended terminating the trial early for efficacy with no safety concerns. Results: In the full analysis population (N=795), nine participants in the taurolidine/heparin arm (n=397; 2%) and 32 participants in the heparin arm (n=398; 8%) had a CRBSI. Event rates per 1000 catheter days were 0.13 and 0.46, respectively, with the difference in time to CRBSI being statistically significant, favoring taurolidine/heparin (P < 0.001). The hazard ratio was 0.29 (95% confidence interval, 0.14 to 0.62), corresponding to a 71% reduction in risk of CRBSIs with taurolidine/heparin versus heparin. There were no significant differences between study arms in time to catheter removal for any reason or loss of catheter patency. The safety of taurolidine/heparin was comparable with that of heparin, and most treatment-emergent adverse events were mild or moderate. Conclusions: Taurolidine/heparin reduced the risk of developing a CRBSI in study participants receiving hemodialysis via CVC compared with heparin with a comparable safety profile. Clinical Trial registry name and registration number: Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection, NCT02651428.

6 December 2017 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Open access
PDF file
BRBruce E. Reidenberg
Bruce E. Reidenberg
CWChristoph Wanner
Christoph Wanner
BPBruce Polsky
Bruce Polsky
MCMariana Castanheira
Mariana Castanheira
ASAlla Shelip
Alla Shelip
APAntony E. Pfaffle
Antony E. Pfaffle
Catheter-related bloodstream infections (CRBSI) are major complications for patients with life-threatening conditions requiring chronic vascular catheterization. The wide range of etiologic microbes and the ongoing development of resistance to antimicrobials with specific mechanisms of action make this an appropriate target for applying a nonspecific antimicrobial therapeutic. Taurolidine hydrolyzes into two antimicrobial moieties, formaldehyde and methylene glycol, which react with microbial surfaces. Neutrolin® (taurolidine, heparin, calcium citrate) was recently introduced in Germany as an antimicrobial catheter lock solution. This postmarketing experience collected data on 201 patients at 20 centers from January 2014 through September 2016. Likely CRBSI was observed in 13 episodes in 47,118 days (0.2759 per 1000 days [0.1468, 0.4718]). Thrombosed catheter was observed in seven catheters in 47,118 days (0.1486 per 1000 days [0.0595, 0.3061]). No adverse drug reactions that led to the discontinuation of Neutrolin® use were reported. Two patients experienced occasional transient dysgeusia. Neutrolin®, when used in conjunction with guideline-based catheter care, showed reduction in the rate of both CRBSI and catheter thrombosis relative to recent historical controls.

9 July 2024 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
BRBruce E. Reidenberg
Bruce E. Reidenberg
SJStephen G. Jenkins
Stephen G. Jenkins
JCJared L. Crandon
Jared L. Crandon
EHElizabeth Hurlburt
Elizabeth Hurlburt
XTXing Tan
Xing Tan
APAntony Pfaffle
Antony Pfaffle
Candida auris is an evolving and concerning global threat. Of particular concern are bloodstream infections related to central venous catheters. We evaluated the activity of taurolidine, a broad-spectrum antimicrobial in catheter lock solutions, against 106 C . auris isolates. Taurolidine was highly active with a MIC 50 /MIC 90 of 512/512 mg/L, over 20-fold lower than lock solution concentrations of ≥13,500 mg/L. Our data demonstrate a theoretical basis for taurolidine-based lock solutions for prevention of C. auris catheter-associated infections.